Stimulant ADHD medication and risk for substance abuse

Journal of Child Psychology and Psychiatry and Allied Disciplines

Volumn 55, Issue 8, 2014, Pages 878-885

  Chang, Zheng ^a   Lichtenstein, Paul ^a   Halldner, Linda ^a   D'Onofrio, Brian ^b   Serlachius, Eva ^a   Fazel, Seena ^c   Larsson, Henrik ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

ADHD; pharmacology; substance abuse

Indexed keywords

CENTRAL STIMULANT AGENT;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; COMPLICATION; EPIDEMIOLOGY; FEMALE; HUMAN; MALE; MIDDLE AGED; PSYCHOLOGY; REGISTER; RISK FACTOR; SUBSTANCE-RELATED DISORDERS; SWEDEN; YOUNG ADULT;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; REGISTRIES; RISK FACTORS; SUBSTANCE-RELATED DISORDERS; SWEDEN; YOUNG ADULT;

EID: 84904057201     PISSN: 00219630     EISSN: 14697610     Source Type: Journal    
DOI: 10.1111/jcpp.12164     Document Type: Article

References (41)

1. Adler, L.A., Zimmerman, B., Starr, H.L., Silber, S., Palumbo, J., Orman, C., &, Spencer, T., (2009). Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. Journal of Clinical Psychopharmacology, 29, 239-247.
2. Banaschewski, T., Coghill, D., Santosh, P., Zuddas, A., Asherson, P., Buitelaar, J.,... &, Taylor, E., (2006). Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. European Child & Adolescent Psychiatry, 15, 476-495. (Pubitemid 46020533)
3. Barkley, R.A., Fischer, M., Smallish, L., &, Fletcher, K., (2003). Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics, 111, 97-109. (Pubitemid 36071038)
4. Biederman, J., Monuteaux, M.C., Spencer, T., Wilens, T.E., Macpherson, H.A., &, Faraone, S.V., (2008). Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: A naturalistic controlled 10-year follow-up study. The American Journal of Psychiatry, 165, 597-603. (Pubitemid 351705336)
5. Boileau, I., Rusjan, P., Houle, S., Wilkins, D., Tong, J., Selby, P.,... &, Kish, S.J., (2008). Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker? The Journal of Neuroscience: the Official Journal of the Society for Neuroscience, 28, 9850-9856.
6. Compton, W.M., Thomas, Y.F., Stinson, F.S., &, Grant, B.F., (2007). Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: Results from the national epidemiologic survey on alcohol and related conditions. Archives of General Psychiatry, 64, 566-576. (Pubitemid 46718289)
7. Elkins, I.J., McGue, M., &, Iacono, W.G., (2007). Prospective effects of attention-deficit/hyperactivity disorder, conduct disorder, and sex on adolescent substance use and abuse. Archives of General Psychiatry, 64, 1145-1152. (Pubitemid 47529338)
8. Faraone, S.V., &, Wilens, T.E., (2007). Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion. The Journal of Clinical Psychiatry, 68 (Suppl 11), 15-22. (Pubitemid 47606857)
9. Findling, R.L., (2008). Evolution of the treatment of attention-deficit/hyperactivity disorder in children: A review. Clinical Therapeutics, 30, 942-957. (Pubitemid 351799870)
10. Findling, R.L., Bukstein, O.G., Melmed, R.D., Lopez, F.A., Sallee, F.R., Arnold, L.E., &, Pratt, R.D., (2008). A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. The Journal of Clinical Psychiatry, 69, 149-159. (Pubitemid 351282009)
11. Fischer, M., &, Barkley, R.A., (2003). Childhood stimulant treatment and risk for later substance abuse. The Journal of Clinical Psychiatry, 64 (Suppl 11), 19-23. (Pubitemid 37169645)
12. Graham, J., &, Coghill, D., (2008). Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: Epidemiology, prevention and management. CNS Drugs, 22, 213-237. (Pubitemid 351263725)
13. Humphreys, K.L., Eng, T., &, Lee, S.S., (2013). Stimulant medication and substance use outcomes: A meta-analysis. JAMA Psychiatry, 70, 740-749.
14. Kendler, K.S., Sundquist, K., Ohlsson, H., Palmer, K., Maes, H., Winkleby, M.A., &, Sundquist, J., (2012). Genetic and familial environmental influences on the risk for drug abuse: A national Swedish adoption study. Archives of General Psychiatry, 69, 690-697.
15. Klein, R.G., Mannuzza, S., Olazagasti, M.A., Roizen, E., Hutchison, J.A., Lashua, E.C., &, Castellanos, F.X., (2012). Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. Archives of General Psychiatry, 69, 1295-1303.
16. Koesters, M., Becker, T., Kilian, R., Fegert, J.M., &, Weinmann, S., (2009). Limits of meta-analysis: Methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. Journal of Psychopharmacology, 23, 733-744.
17. Kollins, S.H., MacDonald, E.K., &, Rush, C.R., (2001). Assessing the abuse potential of methylphenidate in nonhuman and human subjects: A review. Pharmacology, Biochemistry, and Behavior, 68, 611-627.
18. Kooij, S.J., Bejerot, S., Blackwell, A., Caci, H., Casas-Brugue, M., Carpentier, P.J.,... &, Asherson, P., (2010). European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry, 10, 67.
19. Lichtenstein, P., Halldner, L., Zetterqvist, J., Sjolander, A., Serlachius, E., Fazel, S.,... &, Larsson, H., (2012). Medication for attention deficit-hyperactivity disorder and criminality. The New England Journal of Medicine, 367, 2006-2014.
20. Ludvigsson, J.F., Otterblad-Olausson, P., Pettersson, B.U., &, Ekbom, A., (2009). The Swedish personal identity number: Possibilities and pitfalls in healthcare and medical research. European Journal of Epidemiology, 24, 659-667.
21. Mannuzza, S., Klein, R.G., &, Moulton, J.L., 3rd, (2003). Does stimulant treatment place children at risk for adult substance abuse? A controlled, prospective follow-up study. Journal of Child and Adolescent Psychopharmacology, 13, 273-282. (Pubitemid 37288527)
22. Mannuzza, S., Klein, R.G., Truong, N.L., Moulton, J.L., 3rd, Roizen, E.R., Howell, K.H., &, Castellanos, F.X., (2008). Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: Prospective follow-up into adulthood. The American Journal of Psychiatry, 165, 604-609. (Pubitemid 351705337)
23. Newcorn, J.H., Kratochvil, C.J., Allen, A.J., Casat, C.D., Ruff, D.D., Moore, R.J., &, Michelson, D., (2008). Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: Acute comparison and differential response. The American Journal of Psychiatry, 165, 721-730. (Pubitemid 351810541)
24. Official Statistics of Sweden. (2011). Kriminalstatistik 2010 [Criminal statistics]. Stockholm: Brottsförebyggande Rådet
25. Rehm, J., Room, R., van den Brink, W., &, Jacobi, F., (2005). Alcohol use disorders in EU countries and Norway: An overview of the epidemiology. European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology, 15, 377-388. (Pubitemid 40943542)
26. Scheffler, R.M., Hinshaw, S.P., Modrek, S., &, Levine, P., (2007). The global market for ADHD medications. Health Affairs, 26, 450-457.
27. Singh, I., (2008). Beyond polemics: Science and ethics of ADHD. Nature Reviews. Neuroscience, 9, 957-964.
28. Svanborg, P., Thernlund, G., Gustafsson, P.A., Hagglof, B., Poole, L., &, Kadesjo, B., (2009). Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: A randomized, double-blind, placebo-controlled study in stimulant-naive Swedish children and adolescents. European Child and Adolescent Psychiatry, 18, 240-249.
29. Swedish National Institute of Public Health. (2008). Alcohol Statistics 2007. Östersund, Sweden: Swedish National Institute of Public Health.
30. The MTA Cooperative Group (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Archives of General Psychiatry, 56, 1073-1086.
31. Volkow, N.D., &, Swanson, J.M., (2003). Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. The American journal of psychiatry, 160, 1909-1918. (Pubitemid 39619623)
32. Wettermark, B., Hammar, N., Fored, C.M., Leimanis, A., Otterblad Olausson, P., Bergman, U.,... &, Rosen, M., (2007). The new Swedish Prescribed Drug Register-opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiology and Drug Safety, 16, 726-735. (Pubitemid 47180362)
33. WHO. (1992). ICD-10 Classifications of Mental and Behavioural Disorder: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organisation.
34. Wilens, T.E., Adler, L.A., Adams, J., Sgambati, S., Rotrosen, J., Sawtelle, R.,... &, Fusillo, S., (2008). Misuse and diversion of stimulants prescribed for ADHD: A systematic review of the literature. Journal of the American Academy of Child and Adolescent Psychiatry, 47, 21-31.
35. Wilens, T.E., Faraone, S.V., Biederman, J., &, Gunawardene, S., (2003). Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics, 111, 179-185. (Pubitemid 36071051)
36. Winhusen, T.M., Lewis, D.F., Riggs, P.D., Davies, R.D., Adler, L.A., Sonne, S., &, Somoza, E.C., (2011). Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 21, 455-463.
37. Winters, K.C., Lee, S., Botzet, A., Fahnhorst, T., Realmuto, G.M., &, August, G.J., (2011). A prospective examination of the association of stimulant medication history and drug use outcomes among community samples of ADHD youths. Journal of Child and Adolescent Substance Abuse, 20, 314-329.
38. Wise, R.A., (2002). Brain reward circuitry: Insights from unsensed incentives. Neuron, 36, 229-240. (Pubitemid 35217889)
39. Young, J.L., Sarkis, E., Qiao, M., &, Wietecha, L., (2011). Once-daily treatment with atomoxetine in adults with attention-deficit/ hyperactivity disorder: A 24-week, randomized, double-blind, placebo-controlled trial. Clinical Neuropharmacology, 34, 51-60.
40. Zetterqvist, J., Asherson, P., Halldner, L., Langstrom, N., &, Larsson, H., (2012). Stimulant and non-stimulant attention deficit/hyperactivity disorder drug use: Total population study of trends and discontinuation patterns 2006-2009. Acta psychiatrica Scandinavica, 128, 70-77.
41. Zoega, H., Furu, K., Halldorsson, M., Thomsen, P.H., Sourander, A., &, Martikainen, J.E., (2011). Use of ADHD drugs in the Nordic countries: A population-based comparison study. Acta Psychiatrica Scandinavica, 123, 360-367.